Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SYMPHONY101

ABSTRACT: Analysis and functional investigation of lung cancer epistasis by CRISPR screening

PROVIDER: PRJEB82598 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR13982223.fastq.gz	Fastqsanger.gz
	ERR13982224.fastq.gz	Fastqsanger.gz
	ERR13982225.fastq.gz	Fastqsanger.gz
	ERR13982226.fastq.gz	Fastqsanger.gz
	ERR13982227.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 54

Similar Datasets

Project description:CRISPR screening of lung metastatic cells

| PRJNA1079529 | ENA

Targeting the SWI/SNF complexes in POU2F transcription factor driven malignancies [ChIP-seq]

Project description:The SWI/SNF chromatin-remodeling complex, pivotal in transcriptional regulation, has emerged as a significant player in tumorigenesis, unveiling therapeutic targeting prospects in specific malignancies. This investigation accentuates the potential of targeting the SWI/SNF complex in POU2F3-driven Small Cell Lung Cancer (SCLC) and POU2AF1-dependent multiple myelomas. Employing functional CRISPR screening and pharmacological validation, we identified a distinct and biased dependency of POU2F3-driven SCLC cells on the SWI/SNF complex. In vivo studies exhibited significant tumor growth inhibition in POU2F3-driven SCLC xenografts with an orally administered SMARCA2/4 PROTAC degrader. Furthermore, the exploration extended to POU2AF1 complex-dependent B-cell malignancies, revealing similar sensitivity to the SWI/SNF ATPase PROTAC degrader, suggesting a shared therapeutic potential in POU2F complex-driven malignancies. These collective findings highlight the SWI/SNF complex as a promising therapeutic target, catalyzing the advancement of innovative and efficacious treatment approaches to address these transcription factor-driven malignancies, addressing a critical medical challenge.

2024-02-15 | GSE247948 | GEO

Targeting the SWI/SNF complexes in POU2F transcription factor driven malignancies [ATAC-seq]

2024-02-15 | GSE247947 | GEO

Lung cancer prediction

2010-02-28 | GSE12771 | GEO

Homo sapiens

Project description:Kidney cancer metastasis CRISPR screening

| PRJNA1161221 | ENA

Project description:Functional metagenomic screening for anti-CRISPR acitvity

| PRJEB29470 | ENA

Lung cancer prediction

Project description:We generated a blood-derived transcriptional signature that discriminates patients with lung cancer from non-affected smokers. When applied to blood samples from one of the largest prospective population-based cancer studies (the European Prospective Investigation into Cancer and Nutrition), this signature accurately predicted the occurrence of lung cancer in smokers within two years before the onset of clinical symptoms. Such a blood test could be used as a screening tool to enable early diagnosis of lung cancer at a curable stage. All samples were taken from smokers. EPIC cases were taken from the EPIC trial (a large prospective epidemiological trial in Europe, and are incident cases), Cosmos and BC cases are prevalent cases from a Cologne, Germany based epidemiological trial.

2010-02-28 | E-GEOD-12771 | biostudies-arrayexpress

A multiplexed in vivo gene knockout approach to identify cancer drivers in small cell lung cancer [RNAseq]

Project description:We generated a model of lentivirus-initiated mouse small cell lung cancer (SCLC) combined with CRISPR/Cas9 knockout and barcoding. We analyzed tumor suppressive functions of 39 gene candidates using these in vivo CRISPR screening approaches and found Tsc1 to be one of the top tumor suppressor genes in SCLC.

2023-01-09 | GSE198634 | GEO